Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERT-SLE
2024-517753-27-01Phase 3Authorised
- Sponsor
- National Institute of Geriatrics, Rheumatology and Rehabilitation
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial in systemic lupus erythematosus (SLE) comparing Certolizumab pegol with Belimumab (2 arms). Primary endpoint: SRI-4 response at Week 52. Planned start Oct 2025; status: authorised.
02
Drugs
certolizumab pegolbelimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2024-517753-27-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517753-27-01.